CBMG Expands Beijing GMP Facility

CBMG will open a third GMP facility in Beijing to develop their immunotherapy platform, CAR-T.

AsianScientist (May 14, 2015) – Cellular Biomedicine Group Inc. (CBMG), a biomedicine firm engaged in the development of treatments for degenerative and cancerous diseases, has signed a new five-year lease for a 15,000 square feet site slated for the Company’s third good manufacturing practices (GMP) facility, which will also expanded staffing in the Life Science Park, Changping District. This is in anticipation of growth in the Beijing vicinity and further development of the Chimeric Antigen Receptor T cell (CAR-T) platform. CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors.

Approximately half of the site will be a GMP equipped facility to support clinical batch production and commercial scale manufacturing. We expect to complete the state-of-the-art GMP facility in the third quarter of this year.

“Having already established a world-class biomedicine facility in Shanghai, this expansion to Beijing will allow us to prepare for increasing manufacture demand from our immuno-oncology and human adipose-derived mesenchymal progenitor cell (haMPC) platforms in the near future,” said Dr. William (Wei) Cao, CEO of Cellular Biomedicine Group.

“In addition, housing our vertically integrated research and development and production systems in several locations, particularly Beijing, enables the company to deliver consistent quality measures across the whole northern China region, thereby better serving the company’s patient population.”

This announcement follows the acquisition of the Chinese PLA General Hospital’s Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) immuno-oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. The acquisition has allowed CBMG to grow in the immuno-oncology segment and further engage in manufacturing.

———

Source: CBMG.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist